Guardant Health. has filed a patent for a computer technology aimed at precise diagnosis of genetic material states from cell-free DNA samples. The method involves detecting somatic homozygous deletions in BRCA1 or BRCA2 genes to treat cancers associated with homologous recombination deficiency using PARP inhibitors. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Guardant Health Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Precision diagnosis and treatment of cancer with homologous recombination deficiency

Source: United States Patent and Trademark Office (USPTO). Credit: Guardant Health Inc

A recently filed patent (Publication Number: US20240029890A1) outlines a method for treating cancer associated with homologous recombination deficiency (HRD). The method involves determining the presence of a somatic homozygous deletion for a BRCA1 or BRCA2 gene in a sample of cell-free nucleic acid molecules obtained from the subject. This determination is made through a diagnostic assay that compares allelic counts based on germline single nucleotide polymorphism (SNP) positions. If the somatic homozygous deletion is detected, the subject is administered a therapy involving a poly ADP ribose polymerase (PARP) inhibitor to treat the cancer, which could be breast, ovarian, prostate, or pancreatic cancer.

The patent further details the probabilistic distributions and parameters used to generate models of allelic counts for the diagnostic assay, including determining the prevalence of heterozygosity and standard deviation of minor allele frequency in a training set of samples. Additionally, the method involves accessing a plurality of samples, identifying germline deletions, and filtering out samples to identify the presence of the somatic homozygous deletion or heterozygous deletion. The comparison of outputs from the models is done using a log likelihood function, and the therapy administered may include PARP inhibitors such as OLAPARIB, TALAZOPARIB, RUCAPARIB, or NIRAPARIB. Another aspect of the patent focuses specifically on treating ovarian cancer associated with HRD, where the therapy involves administering olaparib to the subject after detecting the somatic homozygous deletion for a gene, which could be BRCA1 or BRCA2, in the sample of cell-free nucleic acid molecules.

To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies